CA2723716A1 - Amelioration de pharmacotherapie par precurseurs arn - Google Patents

Amelioration de pharmacotherapie par precurseurs arn Download PDF

Info

Publication number
CA2723716A1
CA2723716A1 CA2723716A CA2723716A CA2723716A1 CA 2723716 A1 CA2723716 A1 CA 2723716A1 CA 2723716 A CA2723716 A CA 2723716A CA 2723716 A CA2723716 A CA 2723716A CA 2723716 A1 CA2723716 A1 CA 2723716A1
Authority
CA
Canada
Prior art keywords
mirna
seq
cancer
nucleic acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2723716A
Other languages
English (en)
Inventor
Vuong Trieu
Larn Hwang
Neil Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of CA2723716A1 publication Critical patent/CA2723716A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2723716A 2008-05-07 2009-05-07 Amelioration de pharmacotherapie par precurseurs arn Abandoned CA2723716A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5130908P 2008-05-07 2008-05-07
US61/051,309 2008-05-07
PCT/US2009/043123 WO2009137660A2 (fr) 2008-05-07 2009-05-07 Amélioration de pharmacothérapie par précurseurs arn

Publications (1)

Publication Number Publication Date
CA2723716A1 true CA2723716A1 (fr) 2009-11-12

Family

ID=41134520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723716A Abandoned CA2723716A1 (fr) 2008-05-07 2009-05-07 Amelioration de pharmacotherapie par precurseurs arn

Country Status (7)

Country Link
US (1) US20090280167A1 (fr)
EP (1) EP2288704A2 (fr)
JP (1) JP2011519951A (fr)
CN (1) CN102076853A (fr)
AU (1) AU2009244267A1 (fr)
CA (1) CA2723716A1 (fr)
WO (1) WO2009137660A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2235213A2 (fr) * 2007-12-20 2010-10-06 Celgene Corporation Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
WO2011068869A1 (fr) * 2009-12-01 2011-06-09 Abraxis Bioscience, Llc Micro-arn potentialisant 17-aag
WO2011130498A1 (fr) * 2010-04-14 2011-10-20 Abraxis Bioscience, Llc Microarn qui chimiosensibilisent l'effet apoptotique de 17-aag
EP2385120A1 (fr) * 2010-05-04 2011-11-09 Justus-Liebig- Universitat Giessen Utilisation des oligonucleotides antisense anti-miARN pour le traitement de l'hypertension pulmonaire
JPWO2013179672A1 (ja) * 2012-05-31 2016-01-18 武田薬品工業株式会社 子宮内膜症の判定方法
CN103540655A (zh) * 2012-07-16 2014-01-29 复旦大学 Mk5基因在筛选抗肝癌药物中的应用
CN102766696B (zh) * 2012-08-15 2014-05-28 中国人民解放军第二军医大学 早期预测术后认知功能障碍的MicroRNA 572试剂盒及检测方法
CN104884097B (zh) * 2012-11-16 2018-11-06 得克萨斯州大学系统董事会 用于耐药性乳腺癌预后和治疗的作为新治疗助剂和生物标志物的miRNA
EP2931272A1 (fr) * 2012-12-12 2015-10-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Procédés de traitement de la fibrose hépatique et de maladies associées par régulation de l'activité rev-erb
JP2016508520A (ja) * 2013-02-15 2016-03-22 インターナショナル ステム セル コーポレイション 神経変性疾患の治療のための、ヒト多能性幹細胞に由来する神経細胞の使用
CN104117071B (zh) * 2013-04-27 2017-06-13 中国科学院上海药物研究所 microRNA‑491‑3p在拮抗p‑糖蛋白（MDR1）介导的肿瘤耐药中的应用
CN104407151B (zh) * 2014-11-19 2016-06-08 汕头大学医学院 Kindlin-2，Myosin-9和Annexin II三蛋白联合预测食管鳞癌患者预后试剂盒
KR102317700B1 (ko) * 2015-10-07 2021-10-26 아이비바 바이오파마, 인크. 피부 섬유성 장애를 치료하는 조성물 및 방법
EP3444345B1 (fr) * 2016-04-14 2024-07-10 e-NA Biotec Inc. Dérivé d'arnmicro-143
CN105803082A (zh) * 2016-04-26 2016-07-27 中国人民解放军第二军医大学 miR-572作为下肢动脉硬化闭塞症术后再狭窄鉴别诊断标记物及其试剂盒
CN106282212B (zh) * 2016-08-24 2020-03-10 南通大学附属医院 三联人工miRNA抑制VEGFRs制备及其应用
CN106086226B (zh) * 2016-08-25 2020-02-14 朱伟 一种与IgA肾病辅助诊断相关的血浆miRNA标志物及其应用
CN106511263A (zh) * 2016-10-10 2017-03-22 东莞市麦亘生物科技有限公司 一种抗肝癌纳米核酸类口服液及其制备方法
US10874688B2 (en) * 2016-10-31 2020-12-29 Gifu University Double-stranded nucleic acid molecule and use thereof
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US20190388407A1 (en) 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
CN109419773B (zh) * 2017-08-23 2022-06-17 上海交通大学医学院附属仁济医院 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
CN108096265A (zh) * 2017-11-30 2018-06-01 佛山英特医药科技有限公司 miRNA-495在抗肿瘤作用、实施方法及用途
AU2019321429B2 (en) 2018-08-15 2022-12-08 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
CN108904806B (zh) * 2018-08-16 2021-04-06 徐州医科大学 一种miR-497-5p的抑制剂及其在制备治疗肝纤维化的药物中的应用
CN111150853B (zh) * 2020-03-02 2023-09-19 临沂大学 一种肿瘤联合治疗药物载体的制备及应用
WO2021262919A2 (fr) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
CN113637767B (zh) * 2021-08-05 2023-05-05 中国人民解放军东部战区总医院 mir-425-5p在调控卵母细胞成熟中的应用
JP2023138202A (ja) * 2022-03-19 2023-10-02 広海 大谷 生命工学と機械学習を用いたデータベース拡充化事業他ビジネスモデル特許並びに生命工学を用いた薬剤並びにワクチンの発明

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) * 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (fr) * 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Procede de production de produit alimentaire
US4667013A (en) * 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
ATE174058T1 (de) * 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
BR9106702A (pt) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5489743A (en) * 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5858988A (en) * 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6919208B2 (en) * 2000-05-22 2005-07-19 The Children's Hospital Of Philadelphia Methods and compositions for enhancing the delivery of a nucleic acid to a cell
EP2295604B1 (fr) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers
CA2566519C (fr) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micro-arn et utilisations connexes
CA2857881A1 (fr) * 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn

Also Published As

Publication number Publication date
CN102076853A (zh) 2011-05-25
WO2009137660A9 (fr) 2010-01-07
EP2288704A2 (fr) 2011-03-02
AU2009244267A1 (en) 2009-11-12
WO2009137660A2 (fr) 2009-11-12
WO2009137660A3 (fr) 2010-04-22
JP2011519951A (ja) 2011-07-14
US20090280167A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
US20090280167A1 (en) Enhancement of drug therapy by mirna
AU2005282731B2 (en) Regulation of oncogenes by microRNAs
US20090220589A1 (en) Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
Xu et al. Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells
Song et al. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit
US20100310583A1 (en) Let-7 microrna and mimetics thereof as therapeutics for cancer
JP2010537640A (ja) マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
Wang et al. Double-stranded Let-7 mimics, potential candidates for cancer gene therapy
US20220133767A1 (en) Targeting micrornas to overcome drug tolerance and resistance
Durso et al. Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells
WO2011068869A1 (fr) Micro-arn potentialisant 17-aag
WO2011130464A1 (fr) Régulation traductionnelle de sparc par les micro-arn mir29a, b et c
WO2011130498A1 (fr) Microarn qui chimiosensibilisent l'effet apoptotique de 17-aag
Wei et al. Early growth response gene 1, a TRBP binding protein, is involved in miRNA activity of miR-125a-3p in human cells
JP2013039036A (ja) ＨＩＦ−２αの発現を抑制する核酸

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130507